Sanofi SA to Discuss the Collaboration with Sanofi to Deliver Inflammatory Bowel Disease Treatment Call Transcript
Hello, and welcome to the Teva announces collaboration with Sanofi for anti-TL1A Therapy Conference Call. My name is Alex. I'll be coordinating on the call today. (Operator Instructions).
Now I hand it over to your host, Ran Meir, Head of Investor Relations. Please go ahead.
Thank you, Alex. Welcome, everyone, to Teva's investor call where we'll discuss our recent collaboration with Sanofi focusing on Teva's anti-TL1A Assets TEV '574. Please take a moment to review our forward-looking statements on Slide 2. You can find more details on these statements in our PR and Form 8-K released this morning as well as in our SEC Form 10-K and 10-Q.
Today's agenda, feature Richard Francis, Teva's CEO, who will present an overview and the strategic significance of our collaboration. It will be followed by Dr. Eric Hughes, Teva's Head of R&D and Chief Medical Officer; who will be diving into the clinical program. Afterwards, Eli Kalif, our CFO, will elaborate on the transaction details and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
